Articles tagged ‘Dronederone’

The initiation of a multinational, randomized, double-blind Phase IIIb trial, PALLAS to assess the potential clinical benefit of Multaq® (dronedarone) in over 10,000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events, was announced during the Heart Rhythm Society’s 31st Annual Scientific Sessions.

The National Institute for Health and Clinical Excellence (NICE) published their preliminary decision on 24th December 2009, not to recommend the use of the antiarrhythmic, dronedarone, for the treatment of atrial fibrillation (AF) patients on the NHS. The decision has been met with protests from the medical community, politicians and the heart rhythm charity, Arrhythmia Alliance.